Marstacimab clinical trials
Also written PF-06741086.
How each study uses marstacimab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the marstacimab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 11 Oct 2024 · HYMPAVZI · BLA 761369 (FDA, Drugs@FDA)
- European Union
- 18 Nov 2024 · Hympavzi · EMEA/H/C/006240 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
10 studies that test it; most in 2021 (3)
| Year | Studies |
|---|---|
| 2015 | 1 |
| 2017 | 1 |
| 2018 | 1 |
| 2020 | 1 |
| 2021 | 3 |
| 2022 | 1 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 10 · Other 0
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test marstacimab.
Studies
Open first, then newest update. How each study uses marstacimab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 10
- A Study to Assess the Safety of Marstacimab and How Well it Works in People With Mild to Moderate Hemophilia A or B Without InhibitorsRecruitingPhase 3PfizerNCT07923981Written as marstacimab
- Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without InhibitorsRecruitingPhase 3PfizerNCT05145127Written as PF-06741086
- A Study to Learn About How Changing Therapy From Emicizumab to Marstacimab Affects People With the Severe Hemophilia A.RecruitingPhase 1PfizerNCT06703606Written as MARSTACIMAB
- A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia BRecruitingPhase 3PfizerNCT05611801Written as marstacimab
- Study of the Efficacy and Safety PF-06741086 in Adult and Teenage Participants With Severe Hemophilia A or Moderately Severe to Severe Hemophilia BCompletedPhase 3PfizerNCT03938792Written as PF-06741086
- Study to Evaluate Safety and Tolerability of a Single Dose of PF-06741086 in Chinese Adult Participants With Severe HemophiliaCompletedPhase 1PfizerNCT04878731Written as PF-06741086
- A Study of Marstacimab to Compare Prefilled Pen (PFP) Device to Prefilled Syringe (PFS) DeviceTerminatedPhase 1PfizerNCT04832139Written as Marstacimab PFP
- PF-06741086 Long-term Treatment in Severe HemophiliaCompletedPhase 2PfizerNCT03363321Written as PF-06741086
- PF-06741086 Multiple Dose Study in Severe HemophiliaCompletedPhase 2PfizerNCT02974855Written as PF-06741086
- Dose Escalation Study of PF-06741086 In Healthy SubjectsCompletedPhase 1PfizerNCT02531815Written as PF-06741086
Codes
What other systems call marstacimab · ClinicalTrials.gg INT001236
- MeSH (NLM) C000656192marstacimabConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 0UB3OA67O7MARSTACIMABConfirmed FDA, NLM, Wikidata
- Wikidata Q130351881marstacimabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C166436MarstacimabOne source FDA
- DrugBank DB17725One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000656192 | marstacimab | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 0UB3OA67O7 | MARSTACIMAB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q130351881 | marstacimab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C166436 | Marstacimab | One source FDA |
| DrugBank | DB17725 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.